TTK Healthcare Intrinsic Value
TTK Healthcare intrinsic value. TTK Healthcare (TTKHLTCARE) median intrinsic value is ₹528.57 from 9 valuation models (range ₹302–₹968), vs current price ₹1007.40 — -47.5% downside (Trading Above Calculated Value), margin of safety -90.6%. Compare with TTK Healthcare valuation methods to assess whether the stock is under or overvalued.
TTKHLTCARE Valuation Methods Summary — DCF, Graham Number & P/E
TTK Healthcare intrinsic value across 9 models vs current price ₹1007.40 — upside/downside and value range per method. For current market price and key ratios, visit TTK Healthcare share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹627.60 | ₹502.08 - ₹753.12 | -37.7% | EPS: ₹52.30, Sector P/E: 12x |
| Book Value Method | asset | ₹796.43 | ₹716.79 - ₹876.07 | -20.9% | Book Value/Share: ₹796.43, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹550.29 | ₹495.26 - ₹605.32 | -45.4% | Revenue/Share: ₹687.86, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹450.00 | ₹405.00 - ₹495.00 | -55.3% | EBITDA: ₹105.00Cr, EV/EBITDA: 6x |
| PEG Ratio Method | growth | ₹334.72 | ₹301.25 - ₹368.19 | -66.8% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹430.22 | ₹387.20 - ₹473.24 | -57.3% | Revenue Growth: 5.6%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹528.57 | ₹475.71 - ₹581.43 | -47.5% | ROE: 6.6%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹968.09 | ₹871.28 - ₹1064.90 | -3.9% | EPS: ₹52.30, BVPS: ₹796.43 |
| Dividend Yield Method | dividend | ₹302.22 | ₹272.00 - ₹332.44 | -70.0% | DPS: ₹10.00, Target Yield: 3.5% |
TTKHLTCARE Intrinsic Value vs Market Price — All Valuation Models
TTK Healthcare fair value range ₹302–₹968 vs current market price ₹1007.40 across 9 valuation models. Read TTKHLTCARE dividend track record for the complete payout history and dividend yield track record.
TTKHLTCARE Intrinsic Value Analysis — Undervalued or Overvalued?
TTK Healthcare median intrinsic value ₹528.57, current price ₹1007.40 — Trading Above Calculated Value by 47.5%, margin of safety -90.6%.
What is the intrinsic value of TTKHLTCARE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of TTK Healthcare (TTKHLTCARE) is ₹528.57 (median value). With the current market price of ₹1007.40, this represents a -47.5% variance from our estimated fair value.
The valuation range spans from ₹302.22 to ₹968.09, indicating ₹302.22 - ₹968.09.
Is TTKHLTCARE undervalued or overvalued?
Based on our multi-method analysis, TTK Healthcare (TTKHLTCARE) appears to be trading above calculated value by approximately 47.5%.
TTKHLTCARE Financial Health — Key Ratios vs Industry Benchmarks
TTK Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 152.25 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 6.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.72x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
TTKHLTCARE Cash Flow Quality — Operating & Free Cash Flow
TTK Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-21 Cr | ₹-21 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-4 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-5 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-25 Cr | ₹-25 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹45 Cr | ₹30 Cr | Positive Free Cash Flow | 8/10 |